Type 1 Diabetes and Cardiovascular Health

Maria Pesantez, MD[a], Osagie Ebekozien, MD[b],
Francesco Vendrame, MD, PhD[c],*

KEYWORDS

- Type 1 diabetes • Cardiovascular health • Cardiovascular disease risk • Prevention

KEY POINTS

- Type 1 diabetes (T1D) is associated with an increased risk of cardiovascular disease (CVD), which is higher in those diagnosed at early age and with longer disease duration.
- Glycemia is the strongest modifiable risk factor for CVD, although traditional CVD risk factors are involved as well.
- There is an undertreatment of CVD risk factors in T1D, particularly in young adults.
- To promote cardiovascular health (CVH) in T1D, the eight CVH metrics proposed for the general population should adopt targets specific for the T1D population.

INTRODUCTION

In 2010, the American Health Association introduced the concept of cardiovascular health (CVH).[1] The definition was updated in 2022 and now includes four health behaviors and four health factors which, when optimal, are associated with increased longevity and better quality of life.[2] Ideal CVH is defined by the presence of health behaviors such as DASH- and Mediterranean-style eating patterns, physical activity $\geq$150 min/week of moderate-(or greater) intensity activity, never smoking, sleeping 7 -< 9 hours per night, and health factors such as a body mass index (BMI) less than 25 kg/m^2, non-high-density lipoprotein (HDL) cholesterol less than 130 mg/dL, fasting blood glucose less than 100 mg/dL or glycated hemoglobin test (HbA1c) less than 5.7%, and blood pressure less than 120/80 mm Hg^2. Currently, there are no specific recommendations about the use of these metrics in type 1 diabetes (T1D) management. To address this, a comprehensive approach to CVH in T1D is needed, which requires understanding the impact of the disease on the occurrence

[a] Jackson Memorial Hospital, 1450 Northwest 10 Avenue, Miami, FL 33136, USA; [b] T1D Exchange, 101 Federal Street Suite 440, Boston, MA 02110, USA; [c] Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami Miller School of Medicine, 1450 Northwest 10 Avenue, Room 1086, Miami, FL 33136, USA
* Corresponding author.
E-mail address: fvendrame@med.miami.edu

endo.theclinics.com

of CVD, identifying cardiovascular disease (CVD) risk factors and T1D individuals who are at increased risk, and identifying CVH treatment targets and approaches/implementation strategies to reach these goals.

EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN TYPE 1 DIABETES

Mortality rates for people with T1D vary by geographic location but are 3 to 18 times higher than what would be expected in their respective countries.[3] CVD is the leading cause of death, although renal disease is another contributor factor.[3] Although few studies have directly compared CVD mortality in people with T1D and people with type 2 diabetes (T2D), T1D seems to have an impact on mortality which is at least comparable if not higher than T2D.[4,5]

A meta-analysis which included 10 observational studies involving 166,027 patients with T1D and controls from the general population has shown that for people with T1D, the relative risk of coronary artery disease (CAD) is 9.38 (95% CI, 5.56–15.82), and of myocardial infarction is 6.37 (95% CI, 3.81–10.66).[6] In the European Diabetes Prospective Complication Study which analyzed a cohort of 3250 individuals with T1D, the incidence of a cerebrovascular accident was 0.74% per year, almost double of what is reported in the general population which is reported at 0.2% to 0.3% per year.[7] This finding was also supported by Nurses' Health Study.[8] Data about peripheral artery disease (PAD) are mostly derived from studies which focused on amputation. People with T1D have a rate of nontraumatic amputation of 0.4% to 7.2% per year.[9] In a meta-analysis of five studies of people with T1D, each 1% increase in mean HbA1c was associated with an 18% increased risk of PAD.[10]

RISK FACTORS FOR CARDIOVASCULAR DISEASE IN TYPE 1 DIABETES

Several factors increase the risk of CVD in T1D. They are listed in **Box 1** and the most relevant discussed below.

Glycemic Control

Hyperglycemia is a recognized risk factor for the development of both microvascular and macrovascular complications.[11] Hyperglycemia is associated with preclinical atherosclerosis as shown in the Oslo study where a 1% increase in mean HbA1c was associated with a 6.4% increase in coronary vessel stenosis.[12] In the Pittsburgh

---

Box 1
Factors associated with increased risk of cardiovascular disease in type 1 diabetes

Traditional risk factors
  Poor glycemic control
  Dyslipidemia
  High blood pressure
  Diabetic kidney disease
  Obesity
  Smoking

Additional risk factors
  Genetics
  Age of T1D onset
  Female sex
  Cardiac autonomic neuropathy
  Cardiac autoimmunity

Epidemiology of Diabetes Complications (EDC) study for every 1% increase in mean HbA1c, the risk of CVD over 25 years after adjusting for risk factors was increased between 1.13- and 1.26-fold.[13] In the EDC study and Diabetes Control and Complications Trial and follow-up Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC), HbA1c was the strongest risk factor for the first and subsequent CVD event.[11] Hyperglycemia however is not the only determinant of CVD risk in T1D because additional analyses have revealed that other risk factors such as systolic blood pressure and lipids attenuated up to ∼50% the effect of glycemia on the risk of CVD in the DCCT/EDIC study.[14,15] Besides hyperglycemia, there is also some evidence that glycemic variability including hypoglycemia can contribute to future CVD events.[16–18]

Dyslipidemia

Poor glycemic control is associated with hypertriglyceridemia, elevated low-density lipoprotein cholesterol (LDL-C), and lower HDL cholesterol (HDL-C).[19] Data from the Swedish National Registry suggest that LDL-C is a significant predictor of CVD and mortality in T1D, with each 1 mmol/L (38.7 mg/dL) increase in LDL-C associated with 35% to 50% greater risk.[20] An association between LDL-C and CVD in people with T1D has been also reported in studies such as the DCCT/EDIC study and the EDC study.[21,22] In addition, in people with T1D, small dense LDL-C particle size is associated with CVD risk and dysfunctional HDL particles which may become proatherogenic have been reported.[23,24]

High Blood Pressure

Hypertension is a risk factor for CVD in the general population and people with T1D in the DCCT/EDIC study and EDC study.[21,22,25] Hypertension can be a consequence of diabetic kidney disease, but T1D is associated with higher prevalence of hypertension, also in the absence of diabetic kidney disease being three times more common in people with T1D compared with the nondiabetic population.[26]

Diabetic Kidney Disease

Several studies indicate that the diabetic kidney defined as the presence of albuminuria and/or reduced glomerular filtration rate is associated with an increased CVD risk in people with T1D.[22,27,28] The risk of all-cause mortality also increases with the severity of chronic kidney disease.[29] In addition, the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study showed that an increasing albumin excretion and declining glomerular filtration rate predicted the progression of coronary artery calcification in 1066 participants with T1D compared with nondiabetic adults.[30]

Obesity

There is an increasing prevalence of overweight and obesity in people with T1D as shown by the DCCT/EDIC study where the prevalence of obesity increased from 1% of subjects at baseline to 31% after 12 years of follow-up in 2005.[31] This finding is comparable to the one of the EDC study and more recently the T1D Exchange Clinic Network.[32,33] The association of T1D with obesity and comorbidities such as hypertension and dyslipidemia has led to the definition of "double diabetes" to indicate people with T1D and with features of T2D, a condition which increases the CVD risk.[34]

Genetics

A major candidate gene for CVD risk in T1D is the haptoglobin (Hp), an acute phase protein with anti-oxidative properties. Hp is polymorphic with two major alleles and three genotypes.[35] The Hp 2-2 genotype has been associated with the occurrence

of CAD in the DCCT/EDIC study.[36,37] However, the Hp 2-2 genotype has not been identified by genome-wide association studies which instead found associations between increased CVD risk in T1D and single nucleotide polymorphisms, which, however, were weak or not replicated.[38,39]

Age of Type 1 Diabetes Onset

CVD occurs much earlier in people with T1D than in the general population, and premature atherosclerosis may be present in 50% to 70% of individuals by age 45 years.[40–42] In the Swedish National Diabetes registry which included 27,195 people with T1D, those with the disease onset before 10 years of age experienced a 30-fold increased risk of CAD and acute myocardial infarction compared with general population and had increased CVD mortality compared with those who were diagnosed between 26 and 30 years of age after adjusting for diabetes duration.[40]

Female Sex

Women with T1D have a higher risk for CVD than men.[40,41] In the general population, the rates of CAD in premenopausal women are lower than men, but in women with T1D age less than 40 years, the CVD rates are equal in both sex.[43–45] The reasons for these differences are unclear but may be secondary to the undertreatment of risk factors, different fat distribution, and different lipoprotein profiles. Nondiabetic women have a more favorable lipid profile than nondiabetic men, but women with T1D have concentration of LDL-C particles similar to men with T1D.[46–49]

PREDICTION OF CARDIOVASCULAR DISEASE IN TYPE 1 DIABETES

Different approaches have been used to identify people who are at an increased risk of CVD disease and to detect early signs of CVD.

Risk Predication Models

CVD risk calculators are available for the general population and people with T2D, but both the Framingham Risk Score and UK Prospective Diabetes Study (UKPDS) Risk Engine underestimate the CVD risk in T1D.[50] Models which have been developed to address the CVD risk in T1D include the Swedish National Diabetes Register (NDR), the Pittsburgh CHD in Type 1 Diabetes Risk Model, the Steno Type 1 Risk Engine, and the QRISK model.[51–54] Among these models, the Danish Steno Type 1 Risk Engine was externally validated and was superior to the NDR and UKPDS models in predicting the 5-year risk of first fatal or non-fatal CVD event in people with T1D.[53] The British QRISK latest version QRISK3, which accounts for the T1D or T2D status, predicts the 10-year CVD risk with a performance which is higher for people with T1D than T2D.[55] However, CVD risk prediction models for T1D are not widely adopted or recommended by guideline because of lack of international validation.[56]

Imaging to Detect Cardiovascular Disease

Imaging-based tests have been used to detect early signs of CVD.

- Diastolic dysfunction has been reported in adolescents, younger, and older adults with T1D.[57,58] Subclinical systolic dysfunction, which manifests subsequently, can occur in people with T1D but may not be detected by assessing the ejection fraction, which can be normal in the early stages of the disease.[59] Tissue Doppler imaging, speckle tracking echocardiography, and cardiac MRI can be used as screening methods but their use to predict CVD events has not been validated yet.[59–61]

- Arterial stiffness has been described in people with T1D. In particular, aortic stiffness has been identified as an independent maker of all-cause mortality in this population and can be assessed by carotid-femoral pulse wave velocity.[62,63]
- Carotid intima-media thickness (CIMT) is a surrogate marker of CVD disease. However, the DCCT/EDIC study failed to find a significant association between CIMT and subsequent coronary events after adjusting for traditional CVD risk factors.[64]
- Coronary Artery Calcium (CAC) test. Computed tomography is used to measure CAC in the four major coronary arteries. The Multi-Ethnic Study of Atherosclerosis cohort study has demonstrated that the CAC score has a prognostic value in determining the CVD risk in people with T2D.[65] In people with T1D in the EDC study, a score greater than 400 Agatston was the most efficient coronary calcium correlate of CAD.[66] More recent data from the DCCT/EDIC study found that a CAC score greater than 100 Agatston units was significantly associated with an increased risk of the subsequent occurrence of CVD and major cardiovascular events.[67] CAC score could detect asymptomatic atherosclerotic disease in T1D and in the clinical practice favor an aggressive therapy to reduce LDL-C to change the natural course of CVD.[68]

CARDIOVASCULAR DISEASE PREVENTION IN TYPE 1 DIABETES

No randomized trials have been specifically designed to assess the impact of CVD risk reduction strategies in T1D. Recommendations for the reduction of CVD risk in T1D are then mostly derived from data obtained from studies conducted in patients with T2D.

- The DCCT/EDIC study showed that hyperglycemia is modifiable risk factor for CVD in T1D.[69,70] The intensive glycemic control over a mean 6.5 years resulting in a mean HbA1c of 7.2% compared with 9.1% in the conventional therapy group determined a reduction of CVD which persisted beyond the completion of the intervention trial and despite the initial difference in glycemic control was not maintained on follow-up. During the 30 years of follow-up, the incidence of CVD in the former intensive treatment group decreased by 30% and the incidence of major cardiovascular events such as nonfatal myocardial infarction, stroke, or cardiovascular dearth by 32% compared with the former conventional therapy group.[70] Additional analyses have revealed that other risk factors such as systolic blood pressure and lipids attenuated up to ~50% of the effect of glycemia on the risk of CVD, but the association between HbA1c and the risk of CVD remained highly significant even after adjustment for these risk factors.[14,15] Maintaining an optimal glycemic control is then necessary to reduce the risk of CVD. Targeting HbA1c less than 7% or lower if this is not associated with hypoglycemia or adverse effects, or a time in range of 70 to 180 mg/dL greater than 70% is therefore recommended for most people with T1D.[71]
- Some trials investigating the effect of statin therapy in people with T2D have also included people with T1D. A meta-analysis, which included 18,686 people with diabetes from 14 randomized trials of statin therapy, inclusive of 17,220 participants with T2D and 1466 with T1D, has shown a 9% proportional reduction in all-cause mortality and 21% reduction in major vascular events, defined as the composite outcome of myocardial infarction or coronary death, stroke, or coronary revascularization, for each 1 mmol/L (39 mg/dL) reduction in LDL-C.[72] The evidence of benefit in adults with T1D was limited but not different from what

observed in patients with T2D. Recommendations for starting statin treatment for primary prevention in people with T1D are present in different guidelines.[73–75]

- In the EDC study, 605 participants with T1D without known CVD at baseline and followed for 25 years, the optimal blood pressure threshold associated with minimal CVD risk was 120/80 mm Hg.[73,76,77] People with T1D and hypertension should be treated with antihypertensive medications if the blood pressure is persistently above 130/80. The initial treatment can include any of the drug classes demonstrated to reduce CVD in people with diabetes: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, thiazide-like diuretics, or dihydropyridine calcium channel blockers.
- Strategies for weight reduction can include medical nutrition therapy, physical activity, behavioral counseling, pharmacologic therapy, and bariatric surgery. People with T1D may benefit from eating plans that result in an energy deficit and that are lower in carbohydrate and glycemic index and higher in fiber and lean protein.[78] Mediterranean, DASH, vegetarian, or plant-based eating patterns have been shown to be beneficial in T2D, but there is limited evidence to support one specific eating pattern in T1D.[79] Physical activity is associated with weight loss, improved metabolic profile, and reduced CVD mortality in people with T1D.[80,81] The use of adjunct therapies, including glucagon-like peptide-1 analogs in particular, has been associated with weight loss and improved glycemic control but more studies are needed.[82] It is unclear at this time if bariatric surgery and weight loss medications in people with T1D are associated with improved glycemic control or reduced CVD risk.[83]
- Individuals with T1D should engage in 150 minute or more or moderate to vigorous intensity aerobic activity per week and in two to three sessions per week of resistance exercise on nonconsecutive days noting that blood glucose responses to physical activity in T1D are highly variable.[84,85]
- People with T1D should not use cigarettes, other tobacco products and e-cigarettes.[79]

CARDIOVASCULAR HEALTH IN TYPE 1 DIABETES

Better CVH scores are associated with lower risks of CVD disease.[86] CVH metrics can then be applied to people with T1D, but current CVH targets which are recommended for the general population should be modified to reflect the characteristics of T1D and goals associated with lower CVD risk in this population. For example, the measure for blood glucose should the HbA1c less than 7% or lower if this is not associated with hypoglycemia or adverse effect. Ideal blood lipids should be based on LDL-C and reflect the duration of disease and presence of additional risk factors. **Table 1** lists the ideal health behaviors and factors for CVH in adults with T1D.

CONSIDERATIONS

As the incidence of T1D in increasing worldwide and with the constant improvement in medical care and diabetes technology, the expectation is an increased number of older adults living with T1D who were diagnosed when they were children. Data from international registries such as the Type 1 Diabetes Exchange registry in United States and the German/Austrian diabetes-patienten-verlaufsdokumentation (DPV) Registry revealed that less than 40% of people with T1D reached HbA1c, blood pressure, and lipid goals.[87] In addition, more than 80% of young adults aged less than 26 years were not receiving antihypertensive or lipid-lowering medications despite

Table 1
Cardiovascular health goals for adults with type 1 diabetes

Domain	CVH Metric	Quantification
Health behaviors	Diet	Mediterranean-, DASH-style
	Physical activity	$\geq$ 150 min/wk
	Nicotine exposure	Never/quit
	Sleep health	7-<9 h per night
Health factors	BMI	<25 Kg/m^2
	Blood lipids (76)	• LDL-C <100 mg/dL, if age <35 years or T1D duration <10 years
		• LDL-C <70 mg/dL and LDL-C reduction $\geq$50%, if T1D duration $\geq$10 years or another additional risk factor
		• LDL-C< 55 mg/dL and LDL-C reduction $\geq$50%, if T1D duration >20 years or target organ damage or $\geq$3 risk factors
	Blood glucose	HbA1c <7%, time in range 70–180 mg/dL >70%; target can be individualized
	Blood pressure	<120/80 mg/dL; if treated <130/80 mg/dL

Adapted from Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation 2022;146(5):e18-e43.

meeting criteria.[87] The presence of guidelines with different recommendations particularly in younger age groups is another factor which can contribute to different management and clinical inertia for younger people with T1D.[87,88] Strategies to improve CVH should then involve more education for both health care providers and people with diabetes. The development and distribution of educational tools could improve patients' health literacy. An alignment of the different guidelines can also help providers to better navigate the complex process of treatment decision-making. Finally, there is a need to reduce health inequities because with the recent advancements in diabetes technology, health care disparities in T1D treatment have also become more evident.[89]

SUMMARY

As the incidence of T1D in increasing worldwide and with improvements in medical care and diabetes technology, there is an increasing number of people with T1D at risk of CVD. Several CVD risk factors have been identified and therapeutic targets established to promote CVH in T1D. Tools such as risk prediction models and imaging-based tests have not been well validated in T1D, but the CAC test could detect asymptomatic atherosclerotic disease. CVD risk factors are also undertreated. Increased awareness about CVD risk in T1D for both health care providers and individuals with T1D and harmonization of different guidelines are recommended.

CLINICS CARE POINTS

- Discuss with people with type 1 diabetes (T1D) the increased risk of cardiovascular disease (CVD).
- Routinely address CVD risk factors such as elevated blood pressure and lipids in addition to glycemic control.

- Consider the Coronary Artery Calcium (CAC) screening test for better CVD risk stratification.
- Consider early treatment of CVD risk factors, in particular in young adults and women age less than 40 years.

DISCLOSURE

No competing financial interests exist.

REFERENCES

1. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction. Circulation 2010; 121(4):586–613.
2. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation 2022; 146(5):e18–43.
3. Secrest AM, Washington RE, Orchard TJ. Mortality in Type 1 Diabetes. In: Cowie CC, Casagrande SS, Menke A, et al, editors. Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.
4. Juutilainen A, Lehto S, Rönnemaa T, et al. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008;31(4):714–9.
5. Kristófi R, Bodegard J, Norhammar A, et al. Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. Diabetes Care 2021;44(5):1211–8.
6. Cai X, Li J, Cai W, et al. Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. J Diabetes Complicat 2021;35(4):107833.
7. Schram MT, Chaturvedi N, Fuller JH, et al. Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. J Hypertens 2003;21(11):2035–44.
8. Janghorbani M, Hu FB, Willett WC, et al. Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care 2007;30(7):1730–5.
9. Moss SE, Klein R, Klein BE. The 14-year incidence of lower-extremity amputations in a diabetic population. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1999;22(6):951–9.
10. Adler AI, Erqou S, Lima TA, et al. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus-review and meta-analysis. Diabetologia 2010;53(5):840–9.
11. Bebu I, Schade D, Braffett B, et al. Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care 2020;43(4): 867–74.
12. Larsen J, Brekke M, Sandvik L, et al. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 2002;51(8): 2637–41.
13. Miller RG, Anderson SJ, Costacou T, et al. Hemoglobin A1c Level and Cardiovascular Disease Incidence in Persons With Type 1 Diabetes: An Application of Joint

Modeling of Longitudinal and Time-to-Event Data in the Pittsburgh Epidemiology of Diabetes Complications Study. Am J Epidemiol 2018;187(7):1520–9.

14. Bebu I, Braffett BH, Pop-Busui R, et al. The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. Diabetologia 2017;60(10):2084–91.

15. Bebu I, Braffett BH, Orchard TJ, et al. Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care 2019;42(7):1284–9.

16. Snell-Bergeon JK, Roman R, Rodbard D, et al. Glycaemic variability is associated with coronary artery calcium in men with Type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes study. Diabet Med 2010;27(12):1436–42.

17. Fährmann ER, Adkins L, Loader CJ, et al. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Res Clin Pract 2015;107(2):280–9.

18. Khunti K, Davies M, Majeed A, et al. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 2015;38(2):316–22.

19. Vergès B. Dyslipidemia in Type 1 Diabetes: AMaskedDanger. Trends Endocrinol Metab 2020;31(6):422–34.

20. Rawshani A, Rawshani A, Sattar N, et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation 2019;139(16):1900–12.

21. Risk Factors for Cardiovascular Disease in Type 1 Diabetes. Diabetes 2016;65(5):1370–9.

22. Miller RG, Costacou T, Orchard TJ. Risk Factor Modeling for Cardiovascular Disease in Type 1 Diabetes in the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study: A Comparison With the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC). Diabetes 2019;68(2):409–19.

23. Erbey JR, Robbins D, Forrest KY, et al. Low-density lipoprotein particle size and coronary artery disease in a childhood-onset type 1 diabetes population. Metabolism 1999;48(4):531–4.

24. Chapman MJ. HDL functionality in type 1 and type 2 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes 2022;29(2):112–23.

25. Miller RG, Orchard TJ, Costacou T. Risk factors differ by first manifestation of cardiovascular disease in type 1 diabetes. Diabetes Res Clin Pract 2020;163:108141.

26. Rönnback M, Fagerudd J, Forsblom C, et al. Altered age-related blood pressure pattern in type 1 diabetes. Circulation 2004;110(9):1076–82.

27. Soedamah-Muthu SS, Chaturvedi N, Toeller M, et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 2004;27(2):530–7.

28. de Boer IH, Gao X, Cleary PA, et al. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol 2016;11(11):1969–77.

29. Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58(7):1651–8.

30. Maahs DM, Jalal D, Chonchol M, et al. Impaired renal function further increases odds of 6-year coronary artery calcification progression in adults with type 1 diabetes: the CACTI study. Diabetes Care 2013;36(9):2607–14.

31. Diabetes C, Nathan DM, Zinman B, et al. Complications Trial/Epidemiology of Diabetes I, Complications Research G, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169(14):1307–16.

32. Shah VN, Wu M, Polsky S, et al. Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry. J Diabetes Complicat 2018;32(10):961–5.

33. Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med 2010;27(4):398–404.

34. Kietsiriroje N, Pearson S, Campbell M, et al. Double diabetes: A distinct high-risk group? Diabetes Obes Metab 2019;21(12):2609–18.

35. Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005; 1(1):19–28.

36. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57(6):1702–6.

37. Orchard TJ, Backlund JC, Costacou T, et al. Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). J Diabetes Complicat 2016;30(8):1577–84.

38. Charmet R, Duffy S, Keshavarzi S, et al. Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes. Cardiovasc Diabetol 2018;17(1):61.

39. Antikainen AAV, Sandholm N, Trégouët DA, et al. Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. Cardiovasc Res 2021;117(2):600–12.

40. Rawshani A, Sattar N, Franzén S, et al. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet 2018;392(10146):477–86.

41. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313(1):37–44.

42. Chiesa ST, Marcovecchio ML. Preventing Cardiovascular Complications in Type 1 Diabetes: The Need for a Lifetime Approach. Front Pediatr 2021;9:696499.

43. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46(6):760–5.

44. Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999;16(6):466–71.

45. Skrivarhaug T, Bangstad HJ, Stene LC, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006; 49(2):298–305.

46. Miller RG, Costacou T. Glucose Management and the Sex Difference in Excess Cardiovascular Disease Risk in Long-Duration Type 1 Diabetes. Curr Diabetes Rep 2019;19(12):139.

47. Larkin ME, Backlund JY, Cleary P, et al. Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabetic Med 2010; 27(4):451–8.

48. Krishnan S, Fields DA, Copeland KC, et al. Sex differences in cardiovascular disease risk in adolescents with type 1 diabetes. Gend Med 2012;9(4):251–8.

49. Amor AJ, Castelblanco E, Hernández M, et al. Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles. Cardiovasc Diabetol 2020;19(1):126.

50. Zgibor JC, Piatt GA, Ruppert K, et al. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006;29(8):1860–5.

51. Cederholm J, Eeg-Olofsson K, Eliasson B, et al. A new model for 5-year risk of cardiovascular disease in Type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med 2011;28(10):1213–20.

52. Zgibor JC, Ruppert K, Orchard TJ, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in Type 1 Diabetes Risk Model. Diabetes Res Clin Pract 2010;88(3):314–21.

53. Vistisen D, Andersen GS, Hansen CS, et al. Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine. Circulation 2016;133(11):1058–66.

54. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335(7611):136.

55. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.

56. McGurnaghan SJ, McKeigue PM, Read SH, et al. Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia 2021; 64(9):2001–11.

57. Ifuku M, Takahashi K, Hosono Y, et al. Left atrial dysfunction and stiffness in pediatric and adult patients with Type 1 diabetes mellitus assessed with speckle tracking echocardiography. Pediatr Diabetes 2021;22(2):303–19.

58. Hajdu M, Knutsen MO, Vértes V, et al. Quality of glycemic control has significant impact on myocardial mechanics in type 1 diabetes mellitus. Sci Rep 2022;12(1): 20180.

59. Schäfer M, Nadeau KJ, Reusch JEB. Cardiovascular disease in young People with Type 1 Diabetes: Search for Cardiovascular Biomarkers. J Diabetes Complicat 2020;34(10):107651.

60. Palmieri V, Capaldo B, Russo C, et al. Uncomplicated type 1 diabetes and preclinical left ventricular myocardial dysfunction: insights from echocardiography and exercise cardiac performance evaluation. Diabetes Res Clin Pract 2008; 79(2):262–8.

61. von Bibra H, John Sutton M. Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia 2010; 53(6):1033–45.

62. Llauradó G, Ceperuelo-Mallafré V, Vilardell C, et al. Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease: a potential role of low-grade inflammation. Diabetes Care 2012;35(5):1083–9.

63. Helleputte S, Van Bortel L, Verbeke F, et al. Arterial stiffness in patients with type 1 diabetes and its comparison to cardiovascular risk evaluation tools. Cardiovasc Diabetol 2022;21(1):97.

64. Polak JF, Backlund JC, Budoff M, et al. Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. J Am Heart Assoc 2021;10(24):e022922.

65. Malik S, Zhao Y, Budoff M, et al. Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol 2017;2(12): 1332–40.

66. Olson JC, Edmundowicz D, Becker DJ, et al. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000;49(9):1571–8.

67. Budoff M, Backlund JC, Bluemke DA, et al. The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials. JACC Cardiovasc Imaging 2019;12(7 Pt 2): 1341–9.

68. Burge MR, Eaton RP, Schade DS. The Role of a Coronary Artery Calcium Scan in Type 1 Diabetes. Diabetes Technol Therapeut 2016;18(9):594–603.

69. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25): 2643–53.

70. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care 2016;39(5):686–93.

71. ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl 1):S97–110.

72. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607):117–25.

73. ElSayed NA, Aleppo G, Aroda VR, et al. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl 1): S158–90, 10.

74. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation 2014;130(13):1110–30.

75. Authors/Task Force Members, ESC Committee for Practice Guidelines CPG, ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140–205. https://doi.org/10.1016/j.atherosclerosis.2019.08.014.

76. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41(2):255–323.

77. Guo J, Brooks MM, Muldoon MF, et al. Optimal Blood Pressure Thresholds for Minimal Coronary Artery Disease Risk in Type 1 Diabetes. Diabetes Care 2019; 42(9):1692–9.

78. Evert AB, Dennison M, Gardner CD, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019;42(5):731–54.

79. ElSayed NA, Aleppo G, Aroda VR, et al. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Supple 1):S68–96.

80. Tikkanen-Dolenc H, Wadén J, Forsblom C, et al. Physical Activity Reduces Risk of Premature Mortality in Patients With Type 1 Diabetes With and Without Kidney Disease. Diabetes Care 2017;40(12):1727–32.

81. Ostman C, Jewiss D, King N, et al. Clinical outcomes to exercise training in type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2018; 139:380–91.
82. Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care 2016;39(10):1702–10.
83. Vendrame F, Calhoun P, Bocchino LE, et al. Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry. J Diabetes Complicat 2021;35(6):107884.
84. Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016; 39(11):2065–79.
85. Biankin SA, Jenkins AB, Campbell LV, et al. Target-seeking behavior of plasma glucose with exercise in type 1 diabetes. Diabetes Care 2003;26(2):297–301.
86. Bundy JD, Zhu Z, Ning H, et al. Estimated Impact of Achieving Optimal Cardiovascular Health Among US Adults on Cardiovascular Disease Events. J Am Heart Assoc 2021;10(7):e019681.
87. Shah VN, Grimsmann JM, Foster NC, et al. Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (United States) and the prospective diabetes follow-up (Germany/Austria) registries. Diabetes Obes Metab 2020;22(9):1577–85.
88. Varkevisser RDM, Birnie E, Vollenbrock CE, et al. Cardiovascular risk management in people with type 1 diabetes: performance using three guidelines. BMJ Open Diabetes Res Care 2022;10(4). https://doi.org/10.1136/bmjdrc-2022-002765.
89. Majidi S, Ebekozien O, Noor N, et al. Inequities in Health Outcomes in Children and Adults With Type 1 Diabetes: Data From the T1D Exchange Quality Improvement Collaborative. Clin Diabetes 2021;39(3):278–83.